A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors

NCT02162719 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Ipatasertib
DRUG: Paclitaxel
DRUG: Placebo

Sponsor

Genentech, Inc.